[A study of the causes of poor antiviral responses in male chronic hepatitis B patients treated with recombinant interferon-alpha].
OBJECTIVE
To study the causes of poorer antiviral response to neutralizing anti-interferon-alpha antibodies (NA) in male chronic hepatitis B patients treated with recombinant interferon-alpha (rIFN-alpha).


METHODS
Two hundred sixty-nine patients (198 males and 71 females) with histologically proven chronic hepatitis B were treated with 5 MU recombinant interferon-alpha 1b (rIFN-alpha 1b) subcutaneously thrice weekly for 6-37 (median 10.0) months. For each patient, serum HBV DNA levels were detected with fluorescent-quantitative PCR, HBeAg with enzymoimmunoassay, and NA with an antiviral neutralizing biological assay during therapy.


RESULTS
NA was found in 70 (35.4%) of the 198 males and in 15 (21.1%) of the 71 females during treatment (x2 = 4.894, P = 0.027). At the end of treatment combined-response was achieved in 21 (24.7%) of the 85 NA-positive patients and in 100 (54.3%) of the 184 NA-negative cases (x2 = 20.642). Stratification analysis by NA showed that combined-response rate was significantly lower in males than in females (18.6%, 13/70 vs. 53.3%, 8/15, x2 = 8.024) among NA-positive patients while it was similar in males and in females (50.8%, 65/128, vs. 62.5%, 35/56, x2 = 2.156) among NA-negative patients. In stratification analysis by gender, it was significantly lower in NA-positive patients than in NA-negative ones (18.6%, 13/70 vs. 53.3%, 8/15, x2 = 8.024) among males but there was no significant difference between combined-response rates among females.


CONCLUSIONS
The poorer antiviral response to recombinant interferon-alpha in male chronic hepatitis B patients than in female patients is related to the neutralizing anti-interferon antibodies.
Mao
Qian-Guo
QG
Department of Infectious Diseases, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, China.
Liu
Ding-Li
DL
Zhang
Ming-Xia
MX
Feng
Xiao-Rong
XR
Hou
Jin-Lin
JL
D000906:Antibodies / Q000097:blood; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007370:Interferon Type I / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D009500:Neutralization Tests; D011994:Recombinant Proteins; D012737:Sex Factors; D016896:Treatment Outcome
D000906:Antibodies; D000998:Antiviral Agents; D004279:DNA, Viral; D007370:Interferon Type I; D011994:Recombinant Proteins